ABILITA BIO, INC.
Monoclonal antibodies targeting CCR8+ regulatory T cells in the tumor microenvironment for non-small cell lung cancer immunotherapy
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Latest Form D
- $7.5M, Mar 2023
- Total capital
- $9.4M
- Federal grants
- $1.9M
- 5 awards · 2016–2023
- Rank in peer group#81 of 326
- Private capital raised
- $7.5M
- 1 Form D · last Mar 2023
- 43 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 5 pending · first 2019
- Rank in peer group#35 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Novel Anti-CCR8 VHH for the Treatment of NSCLC$399K
- Private capital raisedForm D · SEC · 1st filing$7.5M
- Federal grantHealth and Human S · Phase I · Discovery of Novel Blood-Brain Barrier Targeting Antibodies for the Treatment of Alzheimer's Disease$433K
- Federal grantHealth and Human S · Phase I · Discovery of therapeutic nanobodies targeting the G protein-coupled receptors in the brain for the treatment of Alzheimer Disease$415K
- Federal grantHealth and Human S · Phase I · Development of highly selective therapeutics targeting NaV channel subtypes for the non-opioid treatment of pain$311K
- Federal grantHealth and Human S · Phase I · Discovery of therapeutic antibodies targeting breast cancer metastasis using Enabled G-Protein-Coupled Receptors$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
78months
from ABILITA BIO, INC.’s first federal award to its first private round.
- First federal award · Sep 2016
- Health and Human S · $300K
- First Form D · Mar 2023
- $7.5M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#81 · top 25%
- Granted patents#35 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mauro MileniResearcherExecutive Officer, DirectorLinked by 4 patents · $1.9M in grants as PI
What it has protected
USPTO · 4 granted of 9- GrantedModified Membrane Spanning Proteins And Methods For The Preparation And Use ThereofUSPTOUS 12,351,628
- GrantedModified Membrane Spanning Proteins And Methods For The Preparation And Use ThereofUSPTOUS 11,053,312
- GrantedModified Multispanning Membrane Polypeptides And Methods Of Use Thereof To Screen Therapeutic AgentsUSPTOUS 10,845,367
Show all 9 patent records
- Modified Membrane Spanning Proteins And Methods For The Preparation And Use ThereofJul 8, 2025 · US 12,351,628Granted
- Modified Membrane Spanning Proteins And Methods For The Preparation And Use ThereofJul 6, 2021 · US 11,053,312Granted
- Modified Multispanning Membrane Polypeptides And Methods Of Use Thereof To Screen Therapeutic AgentsNov 24, 2020 · US 10,845,367Granted
- Modified Membrane Spanning Proteins And Methods For The Preparation And Use ThereofMay 14, 2019 · US 10,287,349Granted
- ANTI-CCR8 Antibodies, Conjugates, And Uses ThereofApplication PCTUS2024026654Pending
- Modified Membrane Spanning Proteins And Methods For The Preparation And Use ThereofApplication PCTUS2015058280Pending
- ANTI-CCR8 Antibodies, Conjugates, And Uses ThereofApplication 63498977Pending
- Methods And Platform For Preparing Multispanning Membrane ProteinsApplication PCTUS2017030874Pending
- Methods And Platform For Preparing Multispanning Membrane ProteinsApplication 62331628Pending
Related companies, and why
- SUNFLOWER THERAPEUTICS PBCSimilar federal contract value in Biotech · null in contracts
- NiKang TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Praeventix, LLCSimilar federal contract value in Biotech · null in contracts
- ACELOT, INC.Similar federal contract value in Biotech · null in contracts
- DeuteRx LLCSimilar federal contract value in Biotech · null in contracts
- FGH BIOTECH, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .